$ 0.36
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of ATHA is 0.50 and suggests 39% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
